Journal
PATHOGENS
Volume 8, Issue 4, Pages -Publisher
MDPI
DOI: 10.3390/pathogens8040283
Keywords
neutrophils; biofilms; therapies; enzymes
Categories
Funding
- NIH-NEI [RO1 EY022054]
- Mason Research Fund [054285]
- Canada Foundation for Innovation [JELF 38798]
Ask authors/readers for more resources
Multidrug-resistant (MDR) bacterial infections are a leading cause of mortality, affecting approximately 250,000 people in Canada and over 2 million people in the United States, annually. The lack of efficacy of antibiotic-based treatments is often caused by inability of the drug to penetrate bacterial biofilms in sufficient concentrations, posing a major therapeutic challenge. Here, we review the most recent information about the architecture of Pseudomonas aeruginosa biofilms in vivo and describe how advances in imaging and mass spectroscopy analysis bring about novel therapeutic options and challenge existing dogmas.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available